CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Co...








    



            

                Initial commercial orders for the Apyx One console in South Korea are expected in Q4 2025






    
        
            December 03, 2025 08:00 ET
        

        
             | Source:
            

                Apyx Medical Corporation
            
                

        
    

    

    

    





        
CLEARWATER, Fla., Dec.  03, 2025  (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the approval and commercial launch of the Apyx One console and single-use handpieces in South Korea following the recent regulatory approval by the Ministry of Food and Drug Safety (MFDS). The Company plans to start shipping Apyx One consoles and single-use handpieces to South Korea to fill initial orders starting in the fourth quarter of 2025.  The Apyx One console is a multi-functional generator incorporating an advanced 3-in-1 energy system that enables plastic and cosmetic surgeons to utilize Renuvion technology, together with full monopolar and bipolar energy. Key features of the Apyx One console include adaptive and intuitive touch screens, procedural presets by body part, quantification of energy delivered to a body area, and an advanced gas system that measures and monitors gas volume and usage.  “Seoul is widely regarded as the cosmetic surgery capital of the world, supported by a thriving medical tourism industry. We are excited to launch commercial sales of the Apyx One console in South Korea, where the cosmetic surgery market is estimated to be $1.7 billion in 2024 and projected to exceed $3.9 billion by 20331,” said Charlie Goodwin, President and CEO of Apyx Medical Corporation. “Much like in the U.S. and Europe, the GLP-1 weight-loss drug market in South Korea has grown rapidly over the past two years. As a result, we anticipate there to be a growing number of patients seeking solutions for loose and lax skin following significant weight loss. This is an ideal market for our innovative body contouring technology to build on our success across the U.S. and Europe.”    Jeremy Feffer, Managing Director LifeSci AdvisorsOP: 212-915-2568jfeffer@lifesciadvisors.com  About Apyx Medical Corporation:  Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.  Cautionary Statement on Forward-Looking Statements:  Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, statements regarding the Company’s anticipated public offering, including the completion of the public offering on the anticipated terms and the use of proceeds therefrom, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.  Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.  
            

APYX

Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea

<article>
    <h2>Apyx Medical Corporation Launches Apyx One Console in South Korea</h2>
    <p>Clearwater, Fla. – December 3, 2025 (GLOBE NEWSWIRE) – Apyx Medical Corporation (Nasdaq: APYX), a front-runner in surgical aesthetics, has announced the approval and upcoming commercial launch of its Apyx One console and single-use handpieces in South Korea. This significant development follows the recent regulatory approval from the Ministry of Food and Drug Safety (MFDS). Initial commercial orders are expected to commence shipping in the fourth quarter of 2025.</p>

    <section>
        <h3>Details of the Apyx One Console</h3>
        <p>The Apyx One console is a multi-functional generator utilizing an advanced 3-in-1 energy system. It allows plastic and cosmetic surgeons to leverage Renuvion technology alongside full monopolar and bipolar energy capabilities. Key features of the Apyx One console include:</p>
        <ul>
            <li>Adaptive and intuitive touch screens</li>
            <li>Procedural presets categorized by body part</li>
            <li>Quantification of energy delivered to specific body areas</li>
            <li>An advanced gas system that measures and monitors gas volume and usage</li>
        </ul>
    </section>

    <section>
        <h3>Market Opportunities for Cosmetic Surgery</h3>
        <p>President and CEO of Apyx Medical, Charlie Goodwin, expressed enthusiasm over the launch, stating that Seoul is regarded as the cosmetic surgery capital of the world, thriving in medical tourism. The cosmetic surgery market in South Korea is projected to reach <strong>$3.9 billion</strong> by 2033, up from an estimated <strong>$1.7 billion</strong> in 2024. Goodwin stated, “As the GLP-1 weight-loss drug market in South Korea grows, we expect more patients will seek solutions for loose skin after significant weight loss, making it an ideal market for our body contouring technology.”</p>
    </section>

    <section>
        <h3>About Apyx Medical Corporation</h3>
        <p>Apyx Medical Corporation is dedicated to improving lives through innovative surgical aesthetics products, including Renuvion® and the AYON Body Contouring System™. These products facilitate controlled heat delivery to tissues, helping achieve desired surgical outcomes. The AYON system, which integrates several capabilities like fat removal and tissue contraction, offers a comprehensive platform for body contouring procedures while being backed by over <strong>90 clinical documents</strong> highlighting its effectiveness.</p>
    </section>

    <section>
        <h3>Forward-Looking Statements</h3>
        <p>This announcement contains forward-looking statements, including future revenue projections and regulatory approvals. Apyx Medical emphasizes that these statements may differ materially from actual results, influenced by various risks such as regulatory changes, supply chain fluctuations, and market dynamics. The Company plans to adhere to safe harbor protections for forward-looking statements and does not commit to updating these statements in the future.</p>
    </section>

    <footer>
        <p>For more information about Apyx Medical Corporation and its innovative products, visit <a href="http://www.apyxmedical.com">www.ApyxMedical.com</a>.</p>
    </footer>
</article>

Apyx One console approved for commercial launch in South Korea.
Initial orders expected to start shipping in Q4 2025.
South Korea's cosmetic surgery market projected to grow from $1.7B to $3.9B.
Renuvion technology targets post-weight-loss skin solutions for patients.
Seoul recognized as a global leader in cosmetic surgery and medical tourism.

apyx-medical-corporation-announces-approval-and-commercial-launch-of-apyx-one-console-and-single-use-handpieces-for-cosmetic-surgical-procedures-in-south-korea

Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News